Abstract

Hormone receptor expression patterns often correlate with infiltration of specific lymphocytes in tumors. Specifically, the presence of specific tumor-infiltrating lymphocytes (TILs) with particular hormone receptor expression is reportedly associated with breast cancer, however, this has not been revealed in epithelial ovarian cancer (EOC). Therefore, we investigated the association between hormone receptor expression and TILs in EOC. Here we found that ERα, AR, and GR expression increased in EOC, while PR was significantly reduced and ERβ expression showed a reduced trend compared to normal epithelium. Cluster analysis indicated poor disease-free survival (DFS) in AR+/GR+/PR+ subgroup (triple dominant group); while the Cox proportional-hazards model highlighted the triple dominant group as an independent prognostic factor for DFS. In addition, significant upregulation of FoxP3+ TILs, PD-1, and PD-L1 was observed in the triple dominant group compared to other groups. NanoString analyses further suggested that tumor necrosis factor (TNF) and/or NF-κB signaling pathways were activated with significant upregulation of RELA, MAP3K5, TNFAIP3, BCL2L1, RIPK1, TRAF2, PARP1, and AKT1 in the triple dominant EOC group. The triple dominant subgroup correlates with poor prognosis in EOC. Moreover, the TNF and/or NF-κB signaling pathways may be responsible for hormone-mediated inhibition of the immune microenvironment.

Highlights

  • Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic malignancies, responsible for more than 100,000 cancer-related deaths annually, worldwide [1]

  • glucocorticoid receptor (GR) expression showed the opposite result, and ERβ expression did not show any significant differences, which might be due to differences in protein stability which has been extensively studied in hormone receptors [19]

  • ERβ and GR overexpression were significantly associated with early (p = 0.047; Supplementary Table S1) and advanced Federation of Gynecology and Obstetrics (FIGO) stage (p = 0.050; Supplementary Table S1), respectively

Read more

Summary

Introduction

Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic malignancies, responsible for more than 100,000 cancer-related deaths annually, worldwide [1]. The standard treatment for EOC is primary cytoreductive surgery followed by platinum-based chemotherapy. Emerging evidence has highlighted the potential of targeted therapies, such as anti-angiogenic therapy with bevacizumab or poly (ADP-ribose) polymerase (PARP) inhibitors. Their contribution toward improving survival and prognosis remains modest [2]. Current clinical trials on single-agent programmed cell death protein 1 (PD-1) blockade demonstrated promising results in EOC treatment, the overall response rate is considerably lower than that achieved in melanoma, lung cancer, and renal cell cancer [3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call